Which has stronger earnings & valuation, NCEL or ATRA?

Atara Biotherapeutics has higher revenue and earnings than NLS Pharmaceutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A Atara Biotherapeutics $23.14M 3.33 $32.69M -$0.67 N/A

Does the media favor NCEL or ATRA?

In the previous week, NLS Pharmaceutics and NLS Pharmaceutics both had 1 articles in the media. Atara Biotherapeutics' average media sentiment score of 0.84 beat NLS Pharmaceutics' score of 0.00 indicating that Atara Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NLS Pharmaceutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Atara Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, NCEL or GANX?

NLS Pharmaceutics has higher earnings, but lower revenue than Gain Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A Gain Therapeutics $50K 1,492.75 -$20.16M -$0.58 N/A

Is NCEL or GANX more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets NLS Pharmaceutics N/A N/A N/A Gain Therapeutics N/A -201.44% -136.24%

Which has stronger earnings and valuation, FRMM or NCEL?

NLS Pharmaceutics has lower revenue, but higher earnings than Forum Markets. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Forum Markets $6.55M 10.73 -$450.52M -$36.07 N/A NLS Pharmaceutics N/A N/A -$8.30M N/A N/A

Is FRMM or NCEL more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat Forum Markets' return on equity. Company Net Margins Return on Equity Return on Assets Forum Markets N/A -242.09% -135.46% NLS Pharmaceutics N/A N/A N/A

Does the media refer more to FRMM or NCEL?

In the previous week, Forum Markets had 2 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 3 mentions for Forum Markets and 1 mentions for NLS Pharmaceutics. Forum Markets' average media sentiment score of 0.34 beat NLS Pharmaceutics' score of 0.00 indicating that Forum Markets is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forum Markets 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NLS Pharmaceutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend NCEL or SPRO?

NLS Pharmaceutics currently has a consensus price target of $23.00, indicating a potential upside of 572.51%. Given NLS Pharmaceutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe NLS Pharmaceutics is more favorable than Spero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better valuation & earnings, NCEL or SPRO?

Spero Therapeutics has higher revenue and earnings than NLS Pharmaceutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A Spero Therapeutics $66.80M 1.00 $8.57M $0.24 4.79

Does the media favor NCEL or SPRO?

In the previous week, NLS Pharmaceutics and NLS Pharmaceutics both had 1 articles in the media. NLS Pharmaceutics' average media sentiment score of 0.00 equaled Spero Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NLS Pharmaceutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spero Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate NCEL or XBIT?

NLS Pharmaceutics currently has a consensus price target of $23.00, indicating a potential upside of 572.51%. Given NLS Pharmaceutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe NLS Pharmaceutics is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, NCEL or XBIT?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A XBiotech N/A N/A -$45.54M -$1.32 N/A

Is NCEL or XBIT more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat XBiotech's return on equity. Company Net Margins Return on Equity Return on Assets NLS Pharmaceutics N/A N/A N/A XBiotech N/A -26.10% -25.06%

Does the media favor NCEL or XBIT?

In the previous week, NLS Pharmaceutics and NLS Pharmaceutics both had 1 articles in the media. XBiotech's average media sentiment score of 1.16 beat NLS Pharmaceutics' score of 0.00 indicating that XBiotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NLS Pharmaceutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral XBiotech 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

NLS Pharmaceutics (NCEL) Competitors

$3.42 -0.07 (-2.01%)

As of 08/3/2026 04:00 PM Eastern

Compare

NCEL vs. ATRA, GANX, FRMM, SPRO, and XBIT

Should you buy NLS Pharmaceutics stock or one of its competitors? MarketBeat compares NLS Pharmaceutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NLS Pharmaceutics include Atara Biotherapeutics (ATRA), Gain Therapeutics (GANX), Forum Markets (FRMM), Spero Therapeutics (SPRO), and XBiotech (XBIT).

How does NLS Pharmaceutics compare to Atara Biotherapeutics?

NLS Pharmaceutics (NASDAQ:NCEL) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

Atara Biotherapeutics has higher revenue and earnings than NLS Pharmaceutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Atara Biotherapeutics	$23.14M	3.33	$32.69M	-$0.67	N/A

70.9% of Atara Biotherapeutics shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

NLS Pharmaceutics currently has a consensus price target of $23.00, indicating a potential upside of 572.51%. Atara Biotherapeutics has a consensus price target of $9.50, indicating a potential upside of 11.11%. Given NLS Pharmaceutics' higher probable upside, research analysts plainly believe NLS Pharmaceutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

NLS Pharmaceutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. NLS Pharmaceutics' return on equity of 0.00% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%

In the previous week, NLS Pharmaceutics and NLS Pharmaceutics both had 1 articles in the media. Atara Biotherapeutics' average media sentiment score of 0.84 beat NLS Pharmaceutics' score of 0.00 indicating that Atara Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NLS Pharmaceutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atara Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NLS Pharmaceutics has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market.

Summary

NLS Pharmaceutics and Atara Biotherapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does NLS Pharmaceutics compare to Gain Therapeutics?

NLS Pharmaceutics (NASDAQ:NCEL) and Gain Therapeutics (NASDAQ:GANX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

NLS Pharmaceutics presently has a consensus price target of $23.00, indicating a potential upside of 572.51%. Gain Therapeutics has a consensus price target of $7.50, indicating a potential upside of 328.57%. Given NLS Pharmaceutics' higher possible upside, equities analysts clearly believe NLS Pharmaceutics is more favorable than Gain Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, NLS Pharmaceutics had 1 more articles in the media than Gain Therapeutics. MarketBeat recorded 1 mentions for NLS Pharmaceutics and 0 mentions for Gain Therapeutics. NLS Pharmaceutics' average media sentiment score of 0.00 equaled Gain Therapeutics'average media sentiment score.

Company	Overall Sentiment
NLS Pharmaceutics	Neutral
Gain Therapeutics	Neutral

12.0% of Gain Therapeutics shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by insiders. Comparatively, 4.2% of Gain Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

NLS Pharmaceutics has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

NLS Pharmaceutics' return on equity of 0.00% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Gain Therapeutics	N/A	-201.44%	-136.24%

NLS Pharmaceutics has higher earnings, but lower revenue than Gain Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Gain Therapeutics	$50K	1,492.75	-$20.16M	-$0.58	N/A

Summary

NLS Pharmaceutics beats Gain Therapeutics on 7 of the 11 factors compared between the two stocks.

How does NLS Pharmaceutics compare to Forum Markets?

Forum Markets (NASDAQ:FRMM) and NLS Pharmaceutics (NASDAQ:NCEL) are related small-cap companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

NLS Pharmaceutics' return on equity of 0.00% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forum Markets	N/A	-242.09%	-135.46%
NLS Pharmaceutics	N/A	N/A	N/A

4.1% of Forum Markets shares are held by institutional investors. 25.2% of Forum Markets shares are held by insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Forum Markets had 2 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 3 mentions for Forum Markets and 1 mentions for NLS Pharmaceutics. Forum Markets' average media sentiment score of 0.34 beat NLS Pharmaceutics' score of 0.00 indicating that Forum Markets is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forum Markets	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NLS Pharmaceutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Forum Markets presently has a consensus target price of $10.00, suggesting a potential upside of 90.48%. NLS Pharmaceutics has a consensus target price of $23.00, suggesting a potential upside of 572.51%. Given NLS Pharmaceutics' higher possible upside, analysts clearly believe NLS Pharmaceutics is more favorable than Forum Markets.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forum Markets	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

NLS Pharmaceutics has lower revenue, but higher earnings than Forum Markets.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forum Markets	$6.55M	10.73	-$450.52M	-$36.07	N/A
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

Forum Markets has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

Summary

Forum Markets beats NLS Pharmaceutics on 8 of the 12 factors compared between the two stocks.

How does NLS Pharmaceutics compare to Spero Therapeutics?

NLS Pharmaceutics (NASDAQ:NCEL) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

Spero Therapeutics has higher revenue and earnings than NLS Pharmaceutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Spero Therapeutics	$66.80M	1.00	$8.57M	$0.24	4.79

Spero Therapeutics has a net margin of 24.90% compared to NLS Pharmaceutics' net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat NLS Pharmaceutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Spero Therapeutics	24.90%	35.58%	24.95%

In the previous week, NLS Pharmaceutics and NLS Pharmaceutics both had 1 articles in the media. NLS Pharmaceutics' average media sentiment score of 0.00 equaled Spero Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NLS Pharmaceutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spero Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NLS Pharmaceutics currently has a consensus price target of $23.00, indicating a potential upside of 572.51%. Given NLS Pharmaceutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe NLS Pharmaceutics is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

NLS Pharmaceutics has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market.

25.6% of Spero Therapeutics shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by company insiders. Comparatively, 2.9% of Spero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Spero Therapeutics beats NLS Pharmaceutics on 7 of the 11 factors compared between the two stocks.

How does NLS Pharmaceutics compare to XBiotech?

NLS Pharmaceutics (NASDAQ:NCEL) and XBiotech (NASDAQ:XBIT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A

NLS Pharmaceutics currently has a consensus price target of $23.00, indicating a potential upside of 572.51%. Given NLS Pharmaceutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe NLS Pharmaceutics is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NLS Pharmaceutics' return on equity of 0.00% beat XBiotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
XBiotech	N/A	-26.10%	-25.06%

In the previous week, NLS Pharmaceutics and NLS Pharmaceutics both had 1 articles in the media. XBiotech's average media sentiment score of 1.16 beat NLS Pharmaceutics' score of 0.00 indicating that XBiotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NLS Pharmaceutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
XBiotech	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

55.7% of XBiotech shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by insiders. Comparatively, 30.8% of XBiotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

NLS Pharmaceutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, XBiotech has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

Summary

NLS Pharmaceutics beats XBiotech on 7 of the 10 factors compared between the two stocks.

Get NLS Pharmaceutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NCEL vs. The Competition

Export

Metric	NLS Pharmaceutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$18.66M	$3.55B	$6.86B	$12.44B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	N/A	7.29	280.75	24.99
Price / Sales	N/A	1,267.91	589.64	90.42
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	2.15	16.89	11.03	6.21
Net Income	-$8.30M	-$12.54M	$3.48B	$347.49M
7 Day Performance	-1.72%	0.29%	0.82%	1.29%
1 Month Performance	-11.17%	-7.43%	-4.14%	-3.59%
1 Year Performance	-81.88%	47.14%	61.49%	18.38%

NLS Pharmaceutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NCEL NLS Pharmaceutics	1.5061 of 5 stars	$3.42 -2.0%	$23.00 +572.5%	-81.0%	$18.66M	N/A	N/A	6	Gap Up
ATRA Atara Biotherapeutics	1.5885 of 5 stars	$8.18 +4.7%	$9.50 +16.1%	-26.0%	$73.70M	$23.14M	N/A	330	News Coverage Positive News Upcoming Earnings
GANX Gain Therapeutics	1.96 of 5 stars	$1.72 -0.9%	$7.50 +337.3%	+21.5%	$73.15M	$50K	N/A	20	Positive News Upcoming Earnings
FRMM Forum Markets	3.5284 of 5 stars	$5.38 +1.2%	$10.00 +85.8%	N/A	$72.19M	$6.55M	N/A	7
SPRO Spero Therapeutics	1.0733 of 5 stars	$1.20 flat	N/A	-50.0%	$69.19M	$66.80M	4.98	150	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NCEL) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NLS Pharmaceutics (NCEL) Competitors

NCEL vs. ATRA, GANX, FRMM, SPRO, and XBIT

How does NLS Pharmaceutics compare to Atara Biotherapeutics?

Summary

How does NLS Pharmaceutics compare to Gain Therapeutics?

Summary

How does NLS Pharmaceutics compare to Forum Markets?

Summary

How does NLS Pharmaceutics compare to Spero Therapeutics?

Summary

How does NLS Pharmaceutics compare to XBiotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCEL vs. The Competition

NLS Pharmaceutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NLS Pharmaceutics (NCEL) Competitors

NCEL vs. ATRA, GANX, FRMM, SPRO, and XBIT

How does NLS Pharmaceutics compare to Atara Biotherapeutics?

Which has stronger earnings & valuation, NCEL or ATRA?

Do institutionals and insiders have more ownership in NCEL or ATRA?

Do analysts recommend NCEL or ATRA?

Is NCEL or ATRA more profitable?

Does the media favor NCEL or ATRA?

Which has more risk & volatility, NCEL or ATRA?

Summary

How does NLS Pharmaceutics compare to Gain Therapeutics?

Do analysts prefer NCEL or GANX?

Does the media refer more to NCEL or GANX?

Do institutionals & insiders believe in NCEL or GANX?

Which has more risk & volatility, NCEL or GANX?

Is NCEL or GANX more profitable?

Which has preferable earnings and valuation, NCEL or GANX?

Summary

How does NLS Pharmaceutics compare to Forum Markets?

Is FRMM or NCEL more profitable?

Do institutionals and insiders have more ownership in FRMM or NCEL?

Does the media refer more to FRMM or NCEL?

Do analysts prefer FRMM or NCEL?

Which has stronger earnings and valuation, FRMM or NCEL?

Which has more risk and volatility, FRMM or NCEL?

Summary

How does NLS Pharmaceutics compare to Spero Therapeutics?

Which has better valuation & earnings, NCEL or SPRO?

Is NCEL or SPRO more profitable?

Does the media favor NCEL or SPRO?

Do analysts recommend NCEL or SPRO?

Which has more volatility & risk, NCEL or SPRO?

Do institutionals & insiders have more ownership in NCEL or SPRO?

Summary

How does NLS Pharmaceutics compare to XBiotech?

Which has better earnings & valuation, NCEL or XBIT?

Do analysts rate NCEL or XBIT?

Is NCEL or XBIT more profitable?

Does the media favor NCEL or XBIT?

Do institutionals and insiders have more ownership in NCEL or XBIT?

Which has more volatility & risk, NCEL or XBIT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCEL vs. The Competition

NLS Pharmaceutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools